|230.21||+6.73||+3.01%||Vol 411.29K||1Y Perf -31.13%|
|May 26th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||359.11||Analyst Rating||Strong Buy 1.25|
|Potential %||55.99||Finscreener Ranking||★★★ 49.41|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 47.81|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 59.55|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||5.36||Earnings Rating||Buy|
|Market Cap||11.70B||Earnings Date||4th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||2.71|
|EPS Growth Next 5 Years %||14.00|
|Avg. Weekly Volume||427.16K|
|Avg. Monthly Volume||642.01K|
|Avg. Quarterly Volume||555.89K|
Charles River Laboratories International Inc. (NYSE: CRL) stock closed at 230.21 per share at the end of the most recent trading day (a 3.01% change compared to the prior day closing price) with a volume of 411.29K shares and market capitalization of 11.70B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 18400 people. Charles River Laboratories International Inc. CEO is James C. Foster.
The one-year performance of Charles River Laboratories International Inc. stock is -31.13%, while year-to-date (YTD) performance is -38.9%. CRL stock has a five-year performance of 148.61%. Its 52-week range is between 217.195 and 460.21, which gives CRL stock a 52-week price range ratio of 5.36%
Charles River Laboratories International Inc. currently has a PE ratio of 28.30, a price-to-book (PB) ratio of 4.53, a price-to-sale (PS) ratio of 3.24, a price to cashflow ratio of 17.30, a PEG ratio of 2.32, a ROA of 6.73%, a ROC of 9.15% and a ROE of 18.08%. The company’s profit margin is 11.84%, its EBITDA margin is 23.60%, and its revenue ttm is $3.63 Billion , which makes it $71.44 revenue per share.
Of the last four earnings reports from Charles River Laboratories International Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.71 for the next earnings report. Charles River Laboratories International Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Charles River Laboratories International Inc. is Strong Buy (1.25), with a target price of $359.11, which is +55.99% compared to the current price. The earnings rating for Charles River Laboratories International Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Charles River Laboratories International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Charles River Laboratories International Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.86, ATR14 : 11.03, CCI20 : -109.78, Chaikin Money Flow : -0.04, MACD : -10.87, Money Flow Index : 22.81, ROC : -2.35, RSI : 37.59, STOCH (14,3) : 20.46, STOCH RSI : 0.13, UO : 45.92, Williams %R : -79.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Charles River Laboratories International Inc. in the last 12-months were: Birgit Girshick (Sold 4 850 shares of value $2 133 884 ), David R. Smith (Option Excercise at a value of $1 224 594), David R. Smith (Sold 10 715 shares of value $3 245 875 ), Deborah T. Kochevar (Option Excercise at a value of $417 005), Deborah T. Kochevar (Sold 3 526 shares of value $1 433 070 ), George E. Massaro (Option Excercise at a value of $417 005), George E. Massaro (Sold 2 687 shares of value $1 157 634 ), James C. Foster (Option Excercise at a value of $6 462 233), James C. Foster (Sold 76 984 shares of value $24 283 776 ), Joseph W. LaPlume (Option Excercise at a value of $65 421), Joseph W. LaPlume (Sold 5 634 shares of value $2 052 509 ), Michael Gunnar Knell (Option Excercise at a value of $302 514), Michael Gunnar Knell (Sold 2 327 shares of value $775 715 ), Richard F. Wallman (Sold 7 200 shares of value $2 108 413 ), Victoria L. Creamer (Option Excercise at a value of $1 005 330), Victoria L. Creamer (Sold 6 917 shares of value $2 872 235 ), William D. Barbo (Option Excercise at a value of $1 020 717), William D. Barbo (Sold 12 387 shares of value $4 989 751 )
Tue, 12 Apr 2022 03:35 GMT Analysts Offer Insights on Services Companies: Charles River Labs (CRL) and Discovery Inc (DISCA)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.